Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.57 |
| ▸ | CNR1 | P21554 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | NAAA | Q02083 | 1/20 | 0.53 |
| ▸ | FAAH | O00519 | 4/20 | 0.50 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14951758 | 0.94 | CASP2 (0.66) | CASP2CNR1ALDH1A1NAAAFAAH | |
| SCHEMBL889286 | 0.92 | CASP2 (0.69) | CASP2CNR1ALDH1A1NAAAFAAH | |
| SCHEMBL889167 | 0.92 | CASP2 (0.69) | CASP2CNR1ALDH1A1NAAAFAAH | |
| SCHEMBL889212 | 0.92 | CASP2 (0.69) | CASP2CNR1ALDH1A1NAAAFAAH | |
| SCHEMBL889294 | 0.92 | CASP2 (0.69) | CASP2CNR1ALDH1A1NAAAFAAH | |
| SCHEMBL24393473 | 0.92 | CASP2 (0.69) | CASP2CNR1ALDH1A1NAAAFAAH | |
| SCHEMBL889206 | 0.92 | CASP2 (0.69) | CASP2CNR1ALDH1A1NAAAFAAH | |
| SCHEMBL889156 | 0.92 | CASP2 (0.69) | CASP2CNR1ALDH1A1NAAAFAAH | |
| SCHEMBL889213 | 0.92 | CASP2 (0.69) | CASP2CNR1ALDH1A1NAAAFAAH | |
| SCHEMBL889214 | 0.92 | CASP2 (0.69) | CASP2CNR1ALDH1A1NAAAFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-11685714-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-06-27 | — | — | US | disclosed |
| US-20230190940-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20220016267-A1 | NANOPARTICLES FOR CANCER DETECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-01-20 | — | — | US | disclosed |
| US-20190077752-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-03-14 | — | — | US | disclosed |
| WO-2017147328-A1 | COMPOUNDS FOR BINDING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-08-31 | — | — | WO | disclosed |
| US-20170197919-A1 | 3-(Carboxyethyl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | GRUENENTHAL GMBH (DE) | 2017-07-13 | — | — | US | disclosed |
| US-9644195-B2 | Compounds and methods for purification of serine proteases | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-9200268-B2 | Compounds and methods for purification of serine proteases | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150337285-A1 | COMPOUNDS AND METHODS FOR PURIFICATION OF SERINE PROTEASES | ALEXION PHARMA INTERNATIONAL OPERATIONS UNLIMITED COMPANY (IE) | 2015-11-26 | — | — | US | disclosed |
| US-20140346397-A1 | COMPOUNDS AND METHODS FOR PURIFICATION OF SERINE PROTEASES | ALEXION PHARMA INTERNATIONAL OPERATIONS UNLIMITED COMPANY (IE) | 2014-11-27 | — | — | US | disclosed |
| US-20140186923-A1 | COMPOUNDS AND METHODS FOR PURIFICATION OF SERINE PROTEASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-7732416-B2 | For protecting plants against parasitic feeding pests; also against the infestation of pets, especially cats and dogs, by fleas, ticks and nematodes; pesticides for crop protection | MERIAL LIMITED (US) | 2010-06-08 | — | — | US | disclosed |
| US-7605134-B2 | Pesticides | MERIAL LIMITED (US) | 2009-10-20 | — | — | US | disclosed |
| US-7605134-B2 | Pesticides | MERIAL LIMITED (US) | 2009-10-20 | — | — | US | disclosed |
| EP-1011733-B1 | COMPOSITIONS AND METHODS FOR ENHANCING DELIVERY OF THERAPEUTIC AGENTS TO CELLS | CANJI INC (US) | 2009-06-24 | — | — | EP | disclosed |
| US-5827863-A | Pyrazole derivatives as angiotensin II antagonists | J. URIACH & CIA, S.A. (ES) | 1998-10-27 | — | — | US | disclosed |
| WO-1996004273-A1 | NEW PYRAZOLE DERIVATIVES AS ANGIOTENSIN II ANTAGONIST | J. URIACH & CIA, S.A. (ES) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685714-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BUB1B, KIF5B, TK1 | CASP2 776/4885CNR1 4712/4885ALDH1A1 1427/4885 |
| US-20150337285-A1 | COMPOUNDS AND METHODS FOR PURIFICATION OF SERINE PROTEASES | PRSS1, HPN, PRSS8 | CASP2 638/4885CNR1 4255/4885ALDH1A1 3498/4885 |
| US-20170197919-A1 | 3-(Carboxyethyl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | OPRK1, OPRD1, PKD1 | CASP2 395/4885CNR1 11/4885ALDH1A1 472/4885 |
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CASP2 406/4885CNR1 2493/4885ALDH1A1 2776/4885 |
| US-20230190940-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CASP2 406/4885CNR1 2493/4885ALDH1A1 2776/4885 |
| US-20190077752-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | BUB1B, KIF5B, TK1 | CASP2 776/4885CNR1 4712/4885ALDH1A1 1427/4885 |
| US-20220016267-A1 | NANOPARTICLES FOR CANCER DETECTION | CD63, TP53, NCL | CASP2 1359/4885CNR1 4290/4885ALDH1A1 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.